Arcutis Biotherapeutics Q3 2025 Financial Results and Growth Strategy

Arcutis Biotherapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting significant growth in net product revenue for ZORYVE®, which reached $99.2 million, a 122% increase compared to the same period in 2024. The company also announced the FDA approval of ZORYVE cream 0.05% for treating atopic dermatitis in children aged 2 to 5 years. Arcutis outlined its strategy for sustainable growth, focusing on expanding the ZORYVE franchise, advancing its clinical pipeline, and responsibly allocating capital. The company provided initial 2026 full-year net product sales guidance of $455–$470 million. Additionally, Arcutis management discussed plans to grow the ZORYVE franchise, explore new indications, and build the clinical pipeline during its Investor Day presentation.